REGISTERED NUMBER: |
Sanday Bioscience Limited |
Financial Statements |
for the Year Ended 31st January 2025 |
REGISTERED NUMBER: |
Sanday Bioscience Limited |
Financial Statements |
for the Year Ended 31st January 2025 |
Sanday Bioscience Limited (Registered number: SC685725) |
Contents of the Financial Statements |
for the year ended 31st January 2025 |
Page |
Company information | 1 |
Balance sheet | 2 |
Notes to the financial statements | 3 | to | 5 |
Sanday Bioscience Limited |
Company Information |
for the year ended 31st January 2025 |
Director: |
Registered office: |
Business address: |
Registered number: |
Accountants: |
Academy House |
Shedden Park Road |
Kelso |
Roxburghshire |
TD5 7AL |
Sanday Bioscience Limited (Registered number: SC685725) |
Balance Sheet |
31st January 2025 |
2025 | 2024 |
Notes | £ | £ | £ | £ |
Fixed assets |
Tangible assets | 4 |
Current assets |
Debtors | 5 |
Cash at bank |
Creditors |
Amounts falling due within one year | 6 |
Net current assets |
Total assets less current liabilities |
Provisions for liabilities |
Net assets |
Capital and reserves |
Called up share capital |
Retained earnings |
Shareholders' funds |
The director acknowledges her responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
The financial statements were approved by the director and authorised for issue on |
Sanday Bioscience Limited (Registered number: SC685725) |
Notes to the Financial Statements |
for the year ended 31st January 2025 |
1. | Statutory information |
Sanday Bioscience Limited is a |
2. | Accounting policies |
Basis of preparing the financial statements |
Turnover |
Turnover represents the total invoice value, excluding value added tax, of sales invoiced during the year, or the fair value of services provided for amounts not invoiced at the year end. |
Turnover arising from the sale of goods is recognised when the significant risks and rewards of ownership have passed to the buyer. Turnover arising from the provision of services is recognised as contract activity progresses and the right to consideration is earned. |
Tangible fixed assets |
Office equipment | - |
Tangible fixed assets are stated at cost less accumulated depreciation and accumulated impairment losses. |
Financial instruments |
The following assets and liabilities are classified as financial instruments - trade debtors, accruals and directors' loans. |
Directors' loans (being repayable on demand), trade debtors and accruals are measured at the undiscounted amount of the cash or other consideration expected to be paid or received. |
Financial assets that are measured at amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the Statement of Income and Retained Earnings. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Sanday Bioscience Limited (Registered number: SC685725) |
Notes to the Financial Statements - continued |
for the year ended 31st January 2025 |
2. | Accounting policies - continued |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
Provisions |
Provisions are set up only where it is probable that a present obligation exists as a result of an event prior to the balance sheet date and that a payment will be required in settlement that can be estimated reliably. Where material, provisions are calculated on a discounted basis. |
Going concern |
The director has considered the company's financial position for a minimum period of 12 months and beyond from the date of signing these financial statements and have an expectation that the company should be in a position to continue trading in the current format for the foreseeable future. Accordingly, she continues to adopt the going concern basis in preparing these financial statements |
3. | Employees and directors |
The average number of employees during the year was NIL (2024 - NIL). |
4. | Tangible fixed assets |
Office |
equipment |
£ |
Cost |
Additions |
At 31st January 2025 |
Depreciation |
Charge for year |
At 31st January 2025 |
Net book value |
At 31st January 2025 |
5. | Debtors: amounts falling due within one year |
2025 | 2024 |
£ | £ |
Trade debtors |
Other debtors |
Sanday Bioscience Limited (Registered number: SC685725) |
Notes to the Financial Statements - continued |
for the year ended 31st January 2025 |
6. | Creditors: amounts falling due within one year |
2025 | 2024 |
£ | £ |
Taxation and social security |
Other creditors |
7. | Director's advances, credits and guarantees |
Included within other debtors are the following loans to the director: |
at 31 Jan | Amount | Amount | at 31 Jan |
2024 | Advanced | Repaid | 2025 |
Director | - | 14,144 | (1,320 | ) | 12,824 |
This loan is unsecured, repayable on demand and interest has been charged at the official rates published by HMRC. |
8. | Post balance sheet events |
On 26th March 2025 an interim dividend of £400 per share was declared. |